Evidence-Based First-Line Interventions for IBS
Before reaching for research-chemical peptides, IBS has a short list of interventions with high-quality trial evidence: low-FODMAP diet, enteric-coated peppermint oil, Saccharomyces boulardii, soluble fiber, and ruling out SIBO and celiac.
Irritable Bowel Syndrome has a small, well-characterized set of first-line interventions backed by meta-analyses and society guidelines. They cost far less than peptide stacks and are vastly better evidenced. Low-FODMAP diet. Developed at Monash University in Australia in the late 2000s, the diet eliminates fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (the short-chain carbohydrates that fuel gas-producing colonic fermentation) for 4-6 weeks, then systematically reintroduces them to identify personal triggers. Multiple meta-analyses report symptom improvement in 50-80% of IBS patients, the largest effect size of any single IBS intervention. Long-term adherence is hard; the goal is not permanent restriction but a personalized exclusion list. Enteric-coated peppermint oil (IBgard, Pepogest). L-menthol is a smooth-muscle relaxant that blocks calcium channels in intestinal smooth muscle, reducing spasm. The enteric coating delays release until the small intestine, avoiding lower esophageal sphincter relaxation and heartburn. Multiple positive RCTs and a 2019 meta-analysis show roughly 2x odds of symptom relief versus placebo, particularly for pain and bloating. Saccharomyces boulardii. A non-pathogenic yeast probiotic with the strongest evidence base of any probiotic species — well-established for antibiotic-associated diarrhea and Clostridioides difficile prevention, with growing evidence for IBS-D. Yeast (not bacterial) origin means it is not killed by concurrent antibiotics. Soluble fiber. Psyllium husk (Metamucil, ispaghula) has trial-grade evidence for IBS, particularly IBS-C. Insoluble fiber (wheat bran) can worsen symptoms and is not interchangeable. Start low (3-5g/day) and titrate; rapid escalation causes gas. Diagnostic rule-outs. Up to 30-80% of IBS diagnoses in some series are actually SIBO (small intestinal bacterial overgrowth), treatable with rifaximin. Celiac disease should be screened with tissue transglutaminase IgA before any dietary elimination, because gluten removal invalidates later testing. Bile acid malabsorption accounts for another large minority of 'IBS-D' cases. L-glutamine at 5g/day has one small positive trial in post-infectious IBS and is reasonable to try.